Johnson & Johnson Announces Erleada® (Apalutamide) Treatment Before And After Surgery Reduces Risk Of Recurrence Or Death By 62% Versus Surgery Alone In High-Risk Prostate Cancer
Oct 24 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON ANNOUNCES ERLEADA® (APALUTAMIDE) TREATMENT BEFORE AND AFTER SURGERY REDUCES RISK OF RECURRENCE OR DEATH BY 62% VERSUS SURGERY ALONE IN HIGH-RISK PROSTATE CANCER
Source text: [ID:]
Further company coverage: JNJ.N